FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Avecia anthrax vaccine shows promise

A Phase I trial of Avecia's anthrax vaccine produced data that demonstrates its safety and delivers early signs of efficacy. The U.S. government sees Avecia's development program as a key back-up to the $877 million contract that was signed with VaxGen. VaxGen's program, though, has been afflicted by a series of setbacks that has become the chief example of problems with the country's biodefense program. The UK-based Avecia is working with a $71 million contract. Their new data suggests that the vaccine is generating an immune response but the response is not as strong as the one delivered by the current vaccine.

- here's the AP report on the vaccine data

More stories about Vaxgen   anthrax vaccine   biodefense   immune response  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 24 + 2?
To combat spam, please solve the math question above.